Article

Efficacy of First-Third generation EGFR inhibitor combined with chemotherapy as first-line treatment for advanced lung adenocarcinoma in a real-world setting

2021-12-01

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold>To explore the optimal treatment strategy for patients who harbor sensitive EGFR mutations, a head-to-head study was performed to compare chemotherapy and gefitinib-erlotinip, osimertinib treatment in combination or with either agent alone as first-line therapy, in terms of efficacy and safety.<bold>Methods</bold>A total of 200 untreated patients with advanced lun...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 32c488bb-3b6b-5930-a858-d2d12e8ac7bd
DOI: 10.21203/rs.3.rs-1106177/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy of First-Third generation EGFR inhibitor combined with chemotherapy as first-line treatment for advanced lung adenocarcinoma in a real-world settingDOI 10.21203/rs.3.rs-1106177/v1Read

First-Third generation EGFR inhibitor combined with cytotoxic chemotherapy in elderly Patients with advanced lung adenocarcinom in routine clinical practice-results from A Subgroup AnalysisSemantic proximity Read

First- Third generation EGFR inhibitor combined with cytotoxic chemotherapy in elderly Patients with advanced lung adenocarcinom in routine clinical practice-results from A Subgroup AnalysisSemantic proximity Read

Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials.Semantic proximity Read

Real-Life Use of First-Generation EGFR-TKI with Chemotherapy in EGFR-sensitive Mutations in Non-Small-Cell Lung Cancer: A Single-Center Analysis and Meta-AnalysisSemantic proximity Read

Targeted combination of Bevacizumab demonstrates superior efficacy for stage IV Adenocarcinoma of the lung with EGFR mutation: A Real World StudySemantic proximity Read

First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?Semantic proximity Read

Efficacy Differences of First-line EGFR-TKIs Alone vs. in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alteration(s)Semantic proximity Read

First-generation EGFR-TKI plus chemotherapy versus EGFR-TKI alone as first-line treatment in advanced NSCLC with EGFR activating mutation: a systematic review and meta-analysis of randomized controlled trialsSemantic proximity Read

Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC.Semantic proximity Read

[Application strategies of the third-generation EGFR-TKI in the context of precision medicine].Semantic proximity Read

Efficacy and Acquired Resistance of EGFR-TKI Combined with Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Non-Small Cell Lung Cancer in a Real-world SettingSemantic proximity Read